Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
- 1 November 2019
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 139, 105041
Abstract
No abstract availableKeywords
Funding Information
- Helsinn
This publication has 27 references indexed in Scilit:
- Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy‐Induced Nausea and VomitingThe Journal of Clinical Pharmacology, 2018
- Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based surveyCancer Reports, 2018
- Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nursesSupportive Care in Cancer, 2017
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentJAMA, 2017
- Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcomaCancer Medicine, 2017
- NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetronSupportive Care in Cancer, 2016
- Netupitant PET imaging and ADME studies in humansThe Journal of Clinical Pharmacology, 2013
- Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptivesSupportive Care in Cancer, 2013
- Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancerSupportive Care in Cancer, 2004
- Pharmacokinetics, metabolism and excretion of intravenous [l4C]‐palonosetron in healthy human volunteersBiopharmaceutics & Drug Disposition, 2004